AMANDA BOYD: Open Payments
NPI 1447640321 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,068 in 130 payments from 18 companies in 2025. Trend: 2023 $2,495 · 2024 $1,888 · 2025 $3,068
Food & beverage: $2,959Education: $109
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 17 | $649 |
| Neurocrine BioSciences, Inc. | 15 | $468 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $431 |
| Teva Pharmaceuticals USA, Inc. | 16 | $332 |
| Axsome Therapeutics, Inc. | 5 | $219 |
| ABBVIE INC. | 19 | $186 |
| Otsuka America Pharmaceutical, Inc. | 5 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $116 |
| Supernus Pharmaceuticals, Inc. | 6 | $115 |
| E.R. Squibb & Sons, L.L.C. | 3 | $86 |
Products named: FANAPT, INGREZZA, CAPLYTA, AUSTEDO XR, Auvelity, REXULTI, VRAYLAR, SPRAVATO.
Industry payments across AL — which companies pay providers there.
